- Q4 2023 Vaxcyte Inc Earnings Call TranscriptFeb 27, 2024$81.05 (+2.63%)Earnings
- Vaxcyte Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Vaxcyte Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Vaxcyte Inc VAX-24 Phase 2 65+ Adult Study Results Call TranscriptApr 17, 2023
- Q4 2022 Vaxcyte Inc Earnings Call TranscriptFeb 27, 2023$42.3 (+1.44%)Earnings
- Vaxcyte Inc VAX-24 Phase 1/2 Proof-of-Concept Study Topline Data Call TranscriptOct 24, 2022
- Vaxcyte Inc at Bank of America Healthcare Conference TranscriptMay 10, 2022
- Vaxcyte Inc at Needham Healthcare Conference (Virtual) TranscriptApr 12, 2022
- Q4 2021 Vaxcyte Inc Earnings Call TranscriptFeb 28, 2022$23.17 (+2.52%)Earnings
- Vaxcyte Inc at Guggenheim Vaccine and Infectious Disease Conference (Virtual) TranscriptOct 05, 2021
- Vaxcyte Inc at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 13, 2021
- Q4 2020 Vaxcyte Inc Earnings Call TranscriptMar 29, 2021Earnings
Vaxcyte Inc at Guggenheim Vaccine and Infectious Disease Conference (Virtual) Transcript
So thanks, everybody, for joining us. And this is our 2nd Annual Vaccines and Infectious Diseases Day. We were joined last year by Vaxcyte, so I just want to thank the team for joining us again. Many of you know me, I'm Seamus Fernandez, Guggenheim's global pharma analyst. And with us again this year is Vaxcyte. Many of you know Vaxcyte is a vaccine company with a unique platform that enables the development of vaccines to prevent some of the most common infectious diseases. Their lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine to prevent invasive pneumococcal disease. Many of you know that this is a $6 billion-plus global market, so there is certainly a lot of interest and enthusiasm for this space. I'm going to hand it over to CEO and Founder, Grant Pickering, for opening remarks and introductions to the rest of the team with us today. So, Grant, over to you.
Thank you, Seamus. Let me just start by saying thank you very much for
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)